Novo Nordisk A/S

Novo Nordisk A/S

Verified
Global healthcare company with 95 years of innovation and leadership in diabetes care

Launch date
Employees
Market cap
$240.1b
Net debt
-
Firm valuation
$281.5b (Public information from Aug 2022)
Bagsværd Capital Region of Denmark (HQ)
Corporate Venture Fund: Novo Ventures, Novo Holdings

Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues-14.9b14.9b16.3b16.9b18.8b21.0b
% growth---9 %4 %11 %12 %
EBITDA-7.0b6.8b7.8b8.0b8.6b9.7b
% EBITDA margin-47 %46 %48 %47 %46 %46 %
Profit-5.1b5.2b5.2b5.6b6.4b6.7b
% profit margin-34 %35 %32 %33 %34 %32 %
R&D budget2.0b1.9b1.8b1.7b---
R&D % of revenue-13 %12 %11 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
N/AN/AIPO
Not yet verified
N/A$22mPost IPO Equity
Not yet verified
Total Funding-

Recent News about Novo Nordisk A/S

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit

Investments by Novo Nordisk A/S

Edit
Xellia Pharmaceuticals
ACQUISITION by Novo Nordisk A/S May 2013
EMISPHERE TECHNOLOGIES
ACQUISITION by Novo Nordisk A/S Nov 2020
Dicerna Pharmaceuticals
ACQUISITION by Novo Nordisk A/S Nov 2021
Corvidia
ACQUISITION by Novo Nordisk A/S Jun 2020
Ziylo
ACQUISITION by Novo Nordisk A/S Aug 2018
View 222 more